Sagimet Biosciences, Inc. (SGMT)

Sagimet Biosciences was planning to go public, but the IPO has been withdrawn.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) -11.37M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About SGMT

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of several diseases that result from the overproduction of the fatty acid, palmitate. Based on our clinical and preclinical data, we believe that our wholly-owned pipeline of oral FASN inhibitors has the potential to offer treatments for indications in several therapeutic areas of high unmet medical need including liver diseases and cancers. TVB-2640, whic... [Read more...]

Industry Pharmaceutical Preparations
Founded 2007
CEO George Kemble, Ph.D.
Employees 5
Stock Exchange NASDAQ
Ticker Symbol SGMT
Full Company Profile

Financial Performance

Financial Statements


Sagimet Biosciences IPO Registration Document (S-1)

Sagimet Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.